Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3001 - The role of interim FDG-PET after induction chemotherapy as a prediction of the efficacy of concurrent chemoradiotherapy in locally advanced squamous carcinoma of the head and neck


09 Oct 2016


Poster display


Ka-Rham Kim


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


K. Kim1, H. Shim2, J. Hwang2, S. Cho2, I. Chung2, S.Y. Kwon3, W. Bae2

Author affiliations

  • 1 Hemato-oncology, Chonnam National University Hwasun Hospital, 58128 - Hwasun-Gun/KR
  • 2 Hemato-oncology, Chonnam National University Hwasun Hospital, Hwasun-Gun/KR
  • 3 Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun-Gun/KR


Abstract 3001


Having advantage for organ preservation and systemic control, induction chemotherapy (ICT) using docetaxel, cisplatin and 5-FU (DCF) followed concurrent chemoradiotherapy (CCRT) has been used for nonsurgical management of locally advanced head and neck squamous cell carcinoma (HNSCC). Early prediction of efficacy of CCRT could be helpful to select patients with more effective in surgery than CCRT. We evaluated the role of interim 18-fluoro-2-deoxy-glucose positron emission tomography (FDG-PET) after ICT as a prediction of the efficacy of CCRT and clinical outcomes.


Tumor responses were retrospectively reviewed based on Response Evaluation Criteria in Solid Tumors after ICT and CCRT in locally advanced HNSCC. FDG-PET/CT scans were performed in all patients before and after three cycles of DCF. We examined the association of metabolic response by the percentage decrease of maximum standardized uptake value (SUVmax) after ICT with complete response (CR) to CCRT and clinical outcomes including progression-free survival (PFS) and overall survival (OS).


Forty-four patients with locally advanced HNSCC were evaluated with a median follow-up of 31.7 months. The SUVmax after ICT from baseline was more decreased in CR to CCRT group than non-CR group (78.8% vs. 62.5%, p = 0.004). A 78% decrease of SUVmax after ICT from baseline predicted CR after CCRT (59.3% vs. 17.6%, p = 0.012), PFS (median, not reached vs. 15.0 months, p = 0.002) and OS (median, not reached vs. 43.3 months, p = 0.005) of the patients.


The SUVmax on interim FDG-PET after ICT could be useful to select patients benefitting from CCRT in locally advanced HNSCC and to predict survival outcomes.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings